Loading…
Lobbying Spend
—
Filings
47
Firms Hired
3
Active Period
2021–2026
Client-reported lobbying expenses on LDA filings
Lobbying firms retained by this client; amounts are client-reported expenses when available
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
Biosimilars Access and Affordability Act
2026 · third_quarter · Firm: AVENUE SOLUTIONS
Issues related to Medicare and Medicaid coverage and reimbursement; Issues related to Most Favored Nation (MFN) drug pricing proposal; H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act; Support for H.R. 1492, To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program; H.R. 1672, Maintaining Investments in New Innovation Act; Issues related to Senate Finance Dear Colleague process; H.R. 10628/S. 5571, Biosimilars Access and Affordability Act
Client expense: — · Firm income: $50,000
Matched citations: H.R. 10628
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
2026 · third_quarter · Firm: AVENUE SOLUTIONS
Issues related to Medicare and Medicaid coverage and reimbursement; Issues related to Most Favored Nation (MFN) drug pricing proposal; H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act; Support for H.R. 1492, To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program; H.R. 1672, Maintaining Investments in New Innovation Act; Issues related to Senate Finance Dear Colleague process; H.R. 10628/S. 5571, Biosimilars Access and Affordability Act
Client expense: — · Firm income: $50,000
Matched citations: H.R. 1492
Maintaining Investments in New Innovation Act
2026 · third_quarter · Firm: AVENUE SOLUTIONS
Issues related to Medicare and Medicaid coverage and reimbursement; Issues related to Most Favored Nation (MFN) drug pricing proposal; H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act; Support for H.R. 1492, To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program; H.R. 1672, Maintaining Investments in New Innovation Act; Issues related to Senate Finance Dear Colleague process; H.R. 10628/S. 5571, Biosimilars Access and Affordability Act
Client expense: — · Firm income: $50,000
Matched citations: H.R. 1672
Protecting Patient Access to Cancer and Complex Therapies Act
2026 · third_quarter · Firm: AVENUE SOLUTIONS
Issues related to Medicare and Medicaid coverage and reimbursement; Issues related to Most Favored Nation (MFN) drug pricing proposal; H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act; Support for H.R. 1492, To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program; H.R. 1672, Maintaining Investments in New Innovation Act; Issues related to Senate Finance Dear Colleague process; H.R. 10628/S. 5571, Biosimilars Access and Affordability Act
Client expense: — · Firm income: $50,000
Matched citations: H.R. 4299
Chinese Military and Surveillance Company Sanctions Act of 2024
2026 · third_quarter · Firm: AVENUE SOLUTIONS
Issues related to Medicare and Medicaid coverage and reimbursement; Issues related to Most Favored Nation (MFN) drug pricing proposal; H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act; Support for H.R. 1492, To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program; H.R. 1672, Maintaining Investments in New Innovation Act; Issues related to Senate Finance Dear Colleague process; H.R. 10628/S. 5571, Biosimilars Access and Affordability Act
Client expense: — · Firm income: $50,000
Matched citations: S. 5571
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
2026 · second_quarter · Firm: AVENUE SOLUTIONS
Issues related to Medicare and Medicaid coverage and reimbursement; Issues related to Most Favored Nation (MFN) drug pricing proposal; H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act; Support for H.R. 1492, To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program; H.R. 1672, Maintaining Investments in New Innovation Act; Issues related to Senate Finance Dear Colleague process
Client expense: — · Firm income: $50,000
Matched citations: H.R. 1492
Maintaining Investments in New Innovation Act
2026 · second_quarter · Firm: AVENUE SOLUTIONS
Issues related to Medicare and Medicaid coverage and reimbursement; Issues related to Most Favored Nation (MFN) drug pricing proposal; H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act; Support for H.R. 1492, To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program; H.R. 1672, Maintaining Investments in New Innovation Act; Issues related to Senate Finance Dear Colleague process
Client expense: — · Firm income: $50,000
Matched citations: H.R. 1672
Protecting Patient Access to Cancer and Complex Therapies Act
2026 · second_quarter · Firm: AVENUE SOLUTIONS
Issues related to Medicare and Medicaid coverage and reimbursement; Issues related to Most Favored Nation (MFN) drug pricing proposal; H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act; Support for H.R. 1492, To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program; H.R. 1672, Maintaining Investments in New Innovation Act; Issues related to Senate Finance Dear Colleague process
Client expense: — · Firm income: $50,000
Matched citations: H.R. 4299
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
2026 · first_quarter · Firm: AVENUE SOLUTIONS
Issues related to Medicare and Medicaid coverage and reimbursement; Issues related to Most Favored Nation (MFN) drug pricing proposal; H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act; Support for H.R. 1492, To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program; H.R. 1672, Maintaining Investments in New Innovation Act; Issues related to Senate Finance Dear Colleague process
Client expense: — · Firm income: $50,000
Matched citations: H.R. 1492
Maintaining Investments in New Innovation Act
2026 · first_quarter · Firm: AVENUE SOLUTIONS
Issues related to Medicare and Medicaid coverage and reimbursement; Issues related to Most Favored Nation (MFN) drug pricing proposal; H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act; Support for H.R. 1492, To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program; H.R. 1672, Maintaining Investments in New Innovation Act; Issues related to Senate Finance Dear Colleague process
Client expense: — · Firm income: $50,000
Matched citations: H.R. 1672
Protecting Patient Access to Cancer and Complex Therapies Act
2026 · first_quarter · Firm: AVENUE SOLUTIONS
Issues related to Medicare and Medicaid coverage and reimbursement; Issues related to Most Favored Nation (MFN) drug pricing proposal; H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act; Support for H.R. 1492, To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program; H.R. 1672, Maintaining Investments in New Innovation Act; Issues related to Senate Finance Dear Colleague process
Client expense: — · Firm income: $50,000
Matched citations: H.R. 4299
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
2025 · fourth_quarter · Firm: AVENUE SOLUTIONS
Issues related to Medicare and Medicaid coverage and reimbursement; Issues related to Most Favored Nation (MFN) drug pricing proposal; H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act; Support for H.R. 1492, To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program; H.R. 1672, Maintaining Investments in New Innovation Act
Client expense: — · Firm income: $50,000
Matched citations: H.R. 1492
Maintaining Investments in New Innovation Act
2025 · fourth_quarter · Firm: AVENUE SOLUTIONS
Issues related to Medicare and Medicaid coverage and reimbursement; Issues related to Most Favored Nation (MFN) drug pricing proposal; H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act; Support for H.R. 1492, To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program; H.R. 1672, Maintaining Investments in New Innovation Act
Client expense: — · Firm income: $50,000
Matched citations: H.R. 1672
Protecting Patient Access to Cancer and Complex Therapies Act
2025 · fourth_quarter · Firm: AVENUE SOLUTIONS
Issues related to Medicare and Medicaid coverage and reimbursement; Issues related to Most Favored Nation (MFN) drug pricing proposal; H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act; Support for H.R. 1492, To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program; H.R. 1672, Maintaining Investments in New Innovation Act
Client expense: — · Firm income: $50,000
Matched citations: H.R. 4299
Establishing the congressional budget for the United States Government for fiscal year 2025 and setting forth the appropriate budgetary levels for fiscal years 2026 through 2034.
2025 · second_quarter · Firm: AVENUE SOLUTIONS
Issues related to 340b drug pricing program; Health care issues in H.R.1, To provide for reconciliation pursuant to title II of H. Con. Res. 14 (Public Law No: 119-21);
Client expense: — · Firm income: $50,000
Matched citations: H. Con. Res. 14
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
2025 · second_quarter · Firm: AVENUE SOLUTIONS
Issues related to 340b drug pricing program; Health care issues in H.R.1, To provide for reconciliation pursuant to title II of H. Con. Res. 14 (Public Law No: 119-21);
Client expense: — · Firm income: $50,000
Matched citations: H.R.1
Protecting Patient Access to Cancer and Complex Therapies Act
2025 · second_quarter · Firm: AVENUE SOLUTIONS
Issues related to healthcare access, quality and costs; Issues related to Medicare and Medicaid coverage and reimbursement; H.R. 946/S. 1862, ORPHAN Cures Act; Issues related to Most Favored Nation (MFN) drug pricing proposal; H.R.4299, Protecting Patient Access to Cancer and Complex Therapies Act
Client expense: — · Firm income: $50,000
Matched citations: H.R.4299
Issues related to healthcare access, quality and costs; Issues related to Medicare and Medicaid coverage and reimbursement; H.R. 946/S. 1862, ORPHAN Cures Act; Issues related to Most Favored Nation (MFN) drug pricing proposal; H.R.4299, Protecting Patient Access to Cancer and Complex Therapies Act
Client expense: — · Firm income: $50,000
Matched citations: H.R. 946
Issues related to healthcare access, quality and costs; Issues related to Medicare and Medicaid coverage and reimbursement; H.R. 946/S. 1862, ORPHAN Cures Act; Issues related to Most Favored Nation (MFN) drug pricing proposal; H.R.4299, Protecting Patient Access to Cancer and Complex Therapies Act
Client expense: — · Firm income: $50,000
Matched citations: S. 1862
Full-Year Continuing Appropriations and Extensions Act, 2025
2025 · first_quarter · Firm: AVENUE SOLUTIONS
Issues related to Pandemic and All Hazards Preparedness Act (PAHPA) reauthorization; Issues related to the expiration/extension of Priority Review Vouchers (PRVs) for rare disease; Issues related to 340b drug pricing program; S. 891, Bipartisan Health Care Act H.R. 1968, Full-Year Continuing Appropriations and Extensions Act, 2025 (PL 119-4)
Client expense: — · Firm income: $50,000
Matched citations: H.R. 1968
Issues related to Pandemic and All Hazards Preparedness Act (PAHPA) reauthorization; Issues related to the expiration/extension of Priority Review Vouchers (PRVs) for rare disease; Issues related to 340b drug pricing program; S. 891, Bipartisan Health Care Act H.R. 1968, Full-Year Continuing Appropriations and Extensions Act, 2025 (PL 119-4)
Client expense: — · Firm income: $50,000
Matched citations: S. 891
Issues related to Pandemic and All Hazards Preparedness Act (PAHPA) reauthorization; Issues related to the expiration/extension of Priority Review Vouchers (PRVs) for rare disease; Issues related to 340b drug pricing program; H.R. 10545, American Relief Act, 2025
Client expense: — · Firm income: $50,000
Matched citations: H.R. 10545
Lower Costs, More Transparency Act
2024 · second_quarter · Firm: AVENUE SOLUTIONS
Issues related to Inflation Reduction Act of 2022 (PL 117-169) implementation; Issues related to Medicare Part B, CMS coverage and reimbursement; Issues related to healthcare access, quality and costs; S. 2973, The Modernizing and Ensuring PBM Accountability (MEPA) Act; H.R. 5378, The Lower Costs, More Transparency Act
Client expense: — · Firm income: $50,000
Matched citations: H.R. 5378
Modernizing and Ensuring PBM Accountability Act
2024 · second_quarter · Firm: AVENUE SOLUTIONS
Issues related to Inflation Reduction Act of 2022 (PL 117-169) implementation; Issues related to Medicare Part B, CMS coverage and reimbursement; Issues related to healthcare access, quality and costs; S. 2973, The Modernizing and Ensuring PBM Accountability (MEPA) Act; H.R. 5378, The Lower Costs, More Transparency Act
Client expense: — · Firm income: $50,000
Matched citations: S. 2973
Further Consolidated Appropriations Act, 2024
2024 · first_quarter · Firm: AVENUE SOLUTIONS
Issues related to Pandemic and All Hazards Preparedness Act (PAHPA) reauthorization; Issues related to 340b drug pricing program; Expiring healthcare extenders; S. 1339, The Pharmacy Benefit Manager Reform Act; H.R. 4366, the Consolidated Appropriations Act, 2024 (P.L. 118-42); H.R. 2882, the Further Consolidated Appropriations Act, 2024 (P.L. 118-47); Issues related to 340b
Client expense: — · Firm income: $50,000
Matched citations: H.R. 2882
Source: Senate LDA